1. Home
  2. NDLS vs INKT Comparison

NDLS vs INKT Comparison

Compare NDLS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

N/A

Current Price

$13.74

Market Cap

68.7M

ML Signal

N/A

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

N/A

Current Price

$12.00

Market Cap

59.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NDLS
INKT
Founded
1995
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
59.4M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
NDLS
INKT
Price
$13.74
$12.00
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
N/A
$35.00
AVG Volume (30 Days)
26.2K
6.8K
Earning Date
05-06-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$495,089,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.37
N/A
52 Week Low
$0.47
$8.48
52 Week High
$19.00
$16.80

Technical Indicators

Market Signals
Indicator
NDLS
INKT
Relative Strength Index (RSI) 42.95 57.29
Support Level $12.83 $10.79
Resistance Level $16.10 $12.04
Average True Range (ATR) 0.86 0.58
MACD -0.15 0.04
Stochastic Oscillator 15.92 63.67

Price Performance

Historical Comparison
NDLS
INKT

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Share on Social Networks: